Health Care • Biotechnology: Pharmaceutical Preparations
$12.74 ▼ -0.01
(-0.08%)
MKT CAP: $262.8M • VOL: 40.0K
52W L $11 52W H $17
AMRN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $213.6M | $228.6M | $306.9M |
| YoY Revenue Growth % | -6.5% | -25.5% | — |
| Gross Profit | $120.9M | $81.4M | — |
| Gross Margin % | 56.6% | 35.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$50.2M | -$91.8M | -$67.6M |
| Operating Margin % | -23.5% | -40.2% | -22.0% |
| Net Income (GAAP) | -$38.8M | -$87.0M | -$55.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $6.7M | -$31.0M | $6.9M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $6.7M | -$31.0M | $6.9M |
| FCF Margin % | 3.1% | -13.6% | 2.2% |
| Return on Invested Capital (ROIC %) | -12.2% | -19.9% | — |
| Cash & Short-Term Equivalents | $134.7M | $121.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $459.3M | $486.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AMRN.